Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2025 16:01 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a...
November 05, 2025 07:05 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
November 05, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other...
October 06, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher...
September 19, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and...
September 04, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye shares new preclinical DIO data at virtual KOL eventNimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment...
September 02, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and...
August 27, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
August 21, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
August 07, 2025 16:01 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated...